Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
memo - Magazine of European Medical Oncology
Published in: memo - Magazine of European Medical Oncology 2/2013

01-06-2013 | short review

New developments in acute graft-versus-host disease

Authors: Hildegard T. Greinix, Margit Mitterbauer, MD, Werner Rabitsch, MD, Nina Worel, MD, Ulrike Just, MD, Robert Knobler, MD, Peter Kalhs, MD

Published in: memo - Magazine of European Medical Oncology | Issue 2/2013

Login to get access

Abstract

Allogeneic hematopoietic cell transplantation (HCT) is a well-established curative treatment option for selected patients with hematologic and oncologic diseases. Acute graft-versus-host disease (GvHD) has remained a serious complication of HCT and is associated with high morbidity and mortality especially in patients not responding to first-line therapy with corticosteroids. So far, no standard for salvage therapy of acute corticosteroid-refractory GvHD has been established worldwide. Use of extracorporeal photopheresis results in high response rates, has a steroid-sparing effect and is associated with improved patients’ survival.
Literature
1.
2.
Billingham RE. The biology of graft-versus-host reactions. Harvey Lect. 1966;62:21–78.PubMed
3.
Paczesny S, Hanauer D, Sun Y, et al. New perspectives on the biology of acute GVHD. Bone Marrow Transplant. 2010;45:1–11.PubMedCrossRef
4.
Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11:945–56.PubMedCrossRef
5.
Flowers MED, Inamoto Y, Carpenter PA, et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institute of Health consensus criteria. Blood. 2011;117:3214–9.PubMedCrossRef
6.
Jagasia M, Arora M, Flowers MED, et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood. 2012;119:296–307.PubMedCrossRef
7.
Greinix HT, Loddenkemper C, Pavletic SZ, et al. Diagnosis and staging of chronic graft-versus-host disease in the clinical practice. Biol Blood Marrow Transplant. 2011;17:167–75.PubMedCrossRef
8.
Jagasia M, Giglia J, Chinratanalab W, et al. Incidence and outcome of chronic graft-versus-host disease using National Institutes of Health Consensus criteria. Biol Blood Marrow Transplant. 2007;13:1207–15.PubMedCrossRef
9.
Arora M, Nagaraj S, Witte J, et al. New classification of chronic GVHD: added clarity from the consensus diagnoses. Bone Marrow Transplant. 2009;43:149–53.PubMedCrossRef
10.
Couriel DR, Saliba R, Escalon MP, et al. Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease. Br J Haematol. 2005;130:409–17.PubMedCrossRef
11.
Kuzmina Z, Eder S, Böhm A, et al. Significantly worse survival of patients with NIH-defined chronic graft-versus-host disease and thrombocytopenia or progressive onset type: results of a prospective study. Leukemia. 2012;26:746–56.PubMedCrossRef
12.
Greinix HT. Graft-versus-host disease. Uni-Med Science. 2008.
13.
Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation. 1974;18:295–304.PubMedCrossRef
14.
Rowlings PA, Przepiorka D, Klein JP, et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Brit J Haematol. 1997;97:855–64.CrossRef
15.
Martin PJ, Rizzo JD, Wingard JR, et al. First and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2012;18:1150–63.PubMedCrossRef
16.
Van Lint MT, Uderzo C, Locasciulli A, et al. Early treatment of graft-versus-host disease with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation. Blood. 1998;92:2288–93.PubMed
17.
Mielcarek M, Storer BE, Boeckh M, et al. Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. Blood. 2009;113:2888–94.PubMedCrossRef
18.
MacMillan M, DeFor TE, Weisdorf DJ. The best endpoint for acute GVHD treatment trials. Blood. 2010;115:5412–7.PubMedCrossRef
19.
Greinix HT, Knobler R. Extracorporeal photopheresis. De Gruyter. 2013.
20.
Greinix HT, Knobler RM, Worel N, et al. The effect of intensified extracorporeal photochemotherapy on long-term survival in patients with severe acute graft-versus-host disease. Haematologica. 2006;91:405–8.PubMed
21.
Messina C, Locatelli F, Lanino E, et al. Extracorporeal photochemotherapy for pediatric patients with graft-versus-host disease after hematopoietic stem cell transplantation. Br J Haematol. 2003;22:118–27.CrossRef
22.
Greinix HT, Socie G, Bacigalupo A, et al. Assessing the potential role of photopheresis in hematopoietic stem cell transplant. Bone Marrow Transplant. 2006;38:265–73PubMedCrossRef
23.
Greinix HT, Worel N, Knobler R. Role of extracorporeal photopheresis (ECP) in treatment of steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant. 2010;16:1747–8.PubMedCrossRef
24.
Perfetti P, Carlier P, Strada P, et al. Extracorporeal photopheresis for the treatment of steroid refractory acute GVHD. Bone Marrow Transplant. 2008;42:609–17.PubMedCrossRef
25.
Calore E, Calo A, Tridello G, et al. Extracorporeal photochemotherapy may improve outcome in children with acute GVHD. Bone Marrow Transplant. 2008;42:421–5.PubMedCrossRef
26.
Perotti C, Del Fante C, Tinelli C, et al. Extracorporeal photochemotherapy in graft-versus-host disease: a longitudinal study on factors influencing the response and survival in pediatric patients. Transfusion. 2010;50:1359–69.PubMedCrossRef
27.
Dignan FL, Clark A, Amrolia P, et al. Diagnosis and management of acute graft-versus-host disease. Brit J Haematol. 2012;158:30–45.CrossRef
28.
Wolff D, Ayuk F, Elmaagacli A, et al. Current practice in diagnosis and treatment of acute graft-versus-host disease—results from a survey among German-Austrian-Swiss HSCT centers. Biol Blood Marrow Transplant. 2013 Jan 29. doi:pil:S1083-8791(13)00054-2.
Metadata
Title
New developments in acute graft-versus-host disease
Authors
Hildegard T. Greinix
Margit Mitterbauer, MD
Werner Rabitsch, MD
Nina Worel, MD
Ulrike Just, MD
Robert Knobler, MD
Peter Kalhs, MD
Publication date
01-06-2013
Publisher
Springer Vienna
Published in
memo - Magazine of European Medical Oncology / Issue 2/2013
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-013-0080-1

Other articles of this Issue 2/2013

memo - Magazine of European Medical Oncology 2/2013 Go to the issue

case report

Isolated colonic metastasis from breast cancer 11 years after primary diagnosis

review

Therapy with JAK 1/2 inhibitors for myelofibrosis

short review

The Austrian Competence Network on Mastocytosis (AUCNM): a partner and part of the European ECNM network


review

Biomolecular basis of the role of chronic psychological stress hormone ‘‘glucocorticoid’’ in alteration of cellular immunity during cancer

special report

Recommendations of the Austrian Working Group on Lung Pathology and Oncology for predictive molecular and immunohistochemical testing in non-small cell lung cancer

case report

Broken venous catheter straddling in the pulmonary artery
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits